MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Out-licensing

MuGard Oral Rinse

Access Pharmaceuticals
A clinically-proven mucoadhesive oral rinse which is used in the management of mucositis

Mechanism of action

Mucoadhesive protective coating

Full description

Access Pharmaceuticals' MuGard was developed to provide a drug delivery vehicle to coat the oral mucosa. MuGard may be used without a drug, or by adding a pharmaceutically-active material to the formulation, to treat mucocutaneous diseases and disorders of the oral cavity.

Access Pharmaceuticals has focused on the use of MuGard in the prevention and treatment of mucositis. MuGard was originally developed as a vehicle for an anti-allergic /anti-inflammatory compound. Access conducted a clinical study in patients at high risk of mucositis (cancer patients receiving radiation to the head and neck region) to determine whether the compound could be beneficial in preventing and treating this condition.

The control was MuGard without the drug. While the outcome of the study showed that the compound in MuGard was no better than MuGard alone, many centers reported that patients were benefiting from the rinse.

As a result, Access performed a statistical analysis of study data with matched controls. This retrospective analysis showed that MuGard significantly improved outcome compared with patients on standard care. Access is currently preparing a 510(k) application for marketing approval of MuGard in the United States.

Approval is anticipated in the second half of 2006. Access is seeking a marketing partner for this product. In addition to its use as a device in the management of mucositis, another potential application of MuGard is in topical drug delivery, where the drug formulated in MuGard is either targeted to the mucosa, or for passage through the mucosa for systemic absorption. Access has conducted proof-of-principle studies in an in vitro model.

Development status

Preregistration

Patent information

One patent application

Type of business relationship sought

Licensing and/or co-development

Patent number

One patent application

Licensing contact

Mr Phillip Wise
Vice President, Business Development

Contact directly

Company details

Access Pharmaceuticals

An emerging biotechnology company focused on the development and commercialization of products using the companies targeted delivery systems to improve clinical outcomes for patients.

View profile

Related reports

Are you looking for reports related to this particular subject. Our Reports section is the best place to start.

Related items

Related categories

Clients in focus...

Get the Flash Player to see this rotator.

Partnering discussion free of charge
PharmaVenue
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us